ClinicalTrials.Veeva

Menu
O

Oaxaca Site Management Organization S.C. | Oaxaca, Mexico

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Avelumab
MK-4482
Sunitinib
Ibrutinib
Fulvestrant
Ritonavir
Olaparib
PF-05280014
Trastuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 30 total trials

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll...

Active, not recruiting
Metastatic Cancer
Advanced Gastrointestinal Stromal Tumors
Drug: CGT9486 plus sunitinib
Drug: CGT9486

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to i...

Enrolling
Waldenstrom Macroglobulinemia
Follicular Lymphoma
Drug: Ibrutinib

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

This is a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with metastatic non-small ce...

Enrolling
Non-small Cell Lung Cancer
Drug: MK-1084
Other: Placebo

The purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult pa...

Active, not recruiting
Breast Cancer
Locally Advanced Breast Cancer
Drug: Samuraciclib
Drug: Fulvestrant

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Active, not recruiting
Urinary Bladder Neoplasms
Drug: Cisplatin
Radiation: Hypo-fractioned radiation therapy

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achievi...

Enrolling
Non Small Cell Lung Cancer
Biological: Sacituzumab tirumotecan
Drug: Carboplatin

The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52...

Enrolling
Central Precocious Puberty
Drug: Debio 4326

The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study...

Enrolling
Ulcerative Colitis
Drug: IV Placebo
Drug: SC Placebo

The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study d...

Active, not recruiting
Advanced or Metastatic Breast Cancer
Drug: Everolimus
Drug: Fulvestrant

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall s...

Active, not recruiting
Advanced Malignancies
Urothelial Cancer
Drug: Utomilumab
Drug: Axitinib

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectab...

Active, not recruiting
Advanced Solid Neoplasms
Drug: Olaparib

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: Enlicitide Decanoate

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall s...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Biological: Pembrolizumab
Biological: Sacituzumab tirumotecan

The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal gro...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Drug: H2 Receptor Antagonist
Drug: Dexamethasone (or equivalent)

This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Pemetrexed

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Pfizer logo
Janssen (J&J Innovative Medicine) logo
Arcus Biosciences logo
B
C
C
Debiopharm logo
FibroGen logo
Gilead Sciences logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems